US › Healthcare

Immunome Inc (IMNM)

US · Healthcare · Biotechnology

$25.06+8.91%
Last close · 2026-08-04

Key statistics

Market cap
$2.58B
Forward P/E
0.0
P/B
4.38
Book value
$5.20
EPS (TTM)
$-2.39
52-week high
$27.65
52-week low
$8.66
50-day MA
$21.25
200-day MA
$20.96
Beta
2.07

Analyst view

Analysts rate Immunome Inc a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $35.77.

Shareholding

Insiders
6.61%
Institutions
108.00%

Largest institutional holders

FundStake
FMR Inc14.98%
T. Rowe Price Investment Management,Inc.14.45%
BlackRock Inc7.21%
Redmile Group, LLC4.91%
State Street Corp4.77%
PRIMECAP Management Company4.23%
Wellington Management Company LLP4.18%
Vanguard Capital Management, LLC3.91%

Recent filings & reports

DocumentDate
Shareholder vote results · Q2 20262026-06-12
Quarterly report · Q1 20262026-05-12
Results announced · Q2 20262026-05-12
Proxy statement · Q2 20262026-04-24
Annual report FY20252026-03-03
Results announced · Q1 20262026-03-03
Company announcement · Q4 20252025-12-17
Quarterly report · Q3 20252025-11-06

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Immunome Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.